MD/PhD Physician and Pathologist.
+15 years in cancer research.
Degree in Economics and Business and MBA. Experienced in managing several SMEs.
Engineer, serial entrepreneur, angel investor and director of a business accelerator. Senator at World Business Angels Forum.
MD. Physician. Master in Medical Management and Clinical Management.
Degree in Economics. Experienced in financials. Former Associate Professor.
PhD Molecular Biology. +20 years in Licensing, Business Analytics and Strategic Consulting at Roche, PharmaMar and ActeaVentures.
Katja Görnemann is a certified EFFAS financial analyst specialized in Equity and Fixed Income Investor Relations (IR), Corporate Development, Corporate Finance and Corporate Communication. His professional development has focused on the preparation and execution of IPOs (Gestevisión Telecinco, Talgo), corporate bond issuances, as well as the design and implementation of IR strategic plans in multinational companies from various sectors, including complex corporate situations (Campofrio, debt to equity swap Metrovacesa), refinancing transactions (high yield bonds Campofrio Food Group) and the integration of the Corporate Communication function within IR (Campofrio Food Group). Katja Görnemann has international experience – she has worked in the corporate development team at RWE Energie, Germany – and is fluent in English, Spanish and German.
After leading teams and functions in biopharmaceutical product development in autoimmunity, inflammation, blood disorders, organ transplant rejection and the treatment of acute and chronic viral infections, I’m now charting a new path as an independent consultant leveraging my 25+ years of executive-level strategic experience in the pharma sector.
My career has allowed me to serve as the Chief Medical Officer of several companies, including Provention Bio (focused on intercepting and preventing autoimmune diseases), Global Blood Therapeutics (dedicated to developing novel therapeutics to treat blood-based disorders), Theraclone Sciences (a therapeutic antibody discovery and development company) and ZymoGenetics (focused on developing protein therapeutics).
During my career, I’ve led or played an important role in the development of several approved products: Provention Bio/Sanofi’s teplizumab/TZIELD®, Global Blood Therapeutics/Pfizer’s voxelotor/OXBRYTA®, Roche’s mycophenolate mofetil/CellCept® and daclizumab/Zenapax®; Bristol-Myers Squibb’s belatacept/NULOJIX®; and ZymoGenetics recombinant thrombin/RECOTHROM®.